Also known as: Gilead, Gilead Sciences Inc, Gilead Sciences Inc.
Gilead Sciences is an American biopharmaceutical company focused on discovering, developing, and commercializing medicines in areas including antivirals, oncology, and inflammation. Founded in 1987, it is headquartered in Foster City, California. The company is publicly traded on Nasdaq under GILD.
Compugen said it will release fourth quarter and full year 2025 results on March 2, 2026, and present at the Needham Virtual Healthcare Conference on April 13. The company also outlined its Phase 1 and Phase 3 immuno-oncology pipeline programs.
Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.
South Africa will begin providing lenacapavir on June 5 after delays tied to postimportation testing, while Uganda has launched rollout of the twice-yearly HIV prevention injection in Lira.
Tempus AI signed an agreement to provide precision medicine technology to the University of Southern California. USC will gain access to molecular diagnostics, genomic profiling, clinical trial matching and AI tools.
Kymera said the FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, while Gilead licensed KT-200 and triggered a $45 million milestone payment.
Big drug companies said Trump administration pricing deals had little to no noticeable impact on earnings, though details remain confidential. Novo Nordisk and Eli Lilly described bigger effects tied to lower GLP-1 cash-pay prices and expanded Medicare coverage.
South Africa is working to identify local manufacturers for lenacapavir, a twice-yearly injectable HIV prevention drug that showed near-perfect efficacy in clinical trials. Kenya has already received 21,000 doses of the medication.
The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.
The pharmaceutical industry is experiencing recovery driven by innovation in drug development, aggressive M&A activity, and expansion of drug development services. The sector faces both opportunities and headwinds including pipeline setbacks and regulatory pressures.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
